经皮骨活检指导糖尿病足骨髓炎治疗:多中心随机对照试验方案
BeBoP试验为多中心、随机、医师-研究者-受试者盲法临床试验,比较糖尿病足骨髓炎患者按经皮骨活检培养或溃疡床活检培养指导抗菌治疗的结局差异。计划纳入80例≥18岁糖尿病患者,1:1区组随机分组,主要结局为入组12个月后骨髓炎缓解。
要点
- 国际指南推荐经皮骨活检培养指导抗菌治疗,但实践中常用溃疡床培养。
- BeBoP试验比较两种诊断策略指导治疗对糖尿病足骨髓炎缓解的影响。
- 主要结局为入组12个月后骨髓炎缓解,计划样本量80例。
核心结论
- 旨在比较经皮骨活检与溃疡床活检培养指导抗菌治疗对糖尿病足骨髓炎临床缓解的影响。
研究设计与样本
- 多中心、随机对照、医师-研究者-受试者盲法临床试验,计划纳入80例≥18岁糖尿病足骨髓炎患者,1:1区组随机分层按中心。
关键数值与推荐
- 主要结局为入组12个月后糖尿病足骨髓炎缓解;次要结局包括缓解时间、6和12个月感染部位炎症或溃疡征象、微生物与分子谱、手术干预包括截肢、总抗菌治疗时长、无感染生存天数、不良事件、生活质量与生存。
- 采用意向性治疗和符合方案分析比较结局。
临床怎么用
- 为糖尿病足骨髓炎诊断策略选择提供随机对照证据,辅助临床决策是否采用经皮骨活检培养指导抗菌治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetic foot osteomyelitis (DFO) poses a major disease burden. It can generally be treated with long-term antibacterial therapy. International guidelines recommend to base antibacterial therapy choices on percutaneous bone biopsy culture, while in practice, therapy is frequently based on (less invasive) ulcer bed cultures. It is currently unknown if treatment outcomes of DFO differ depending on the chosen diagnostic strategy. METHODS: The BeBoP trial is a multicentre; randomised controlled; physician-, researcher- and subject-blinded; clinical trial comparing two diagnostic strategies in persons with DFO. Culture-directed antibacterial therapy will be based on either percutaneous bone biopsy culture results (intervention group) or ulcer bed biopsy culture results (comparison group). We will enrol 80 subjects with diabetes mellitus (≥ 18 years) and DFO, and we will use block randomisation stratified per centre to randomise them in a 1:1 allocation. The primary outcome is remission of DFO 12 months after enrolment. The secondary outcomes are the time to remission, signs of inflammation or ulceration at the primary location of infection at 6 and 12 months, microbiological and molecular profiles of culture outcomes, surgical interventions including amputation, total antibacterial therapy duration, infection-free survival days, adverse events, quality of life and survival. We will compare the outcomes by intention-to-treat and per-protocol analysis. DISCUSSION: We aim to compare clinical remission in persons with DFO treated with antibacterial therapy based on either percutaneous bone biopsy culture results or ulcer bed biopsy culture results. TRIAL REGISTRATION: Netherlands Trial Register NL 7582 . Registered on 05 March 2019.
引用
- Gramberg MCTT, Lagrand RS, Sabelis LWE, et al. Using a BonE BiOPsy (BeBoP) to determine the causative agent in persons with diabetes and foot osteomyelitis: study protocol for a multicentre, randomised controlled trial. Trials. 2021. PMID: 34344428. doi:10.1186/s13063-021-05472-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。